Dataset Information

Different Heart Rate Patterns During Cardio-Pulmonary Exercise (CPX) Testing in Individuals With Type 1 Diabetes.

ABSTRACT: To investigate the heart rate during cardio-pulmonary exercise (CPX) testing in individuals with type 1 diabetes (T1D) compared to healthy (CON) individuals. Fourteen people (seven individuals with T1D and seven CON individuals) performed a CPX test until volitional exhaustion to determine the first and second lactate turn points (LTP1 and LTP2), ventilatory thresholds (VT1 and VT2), and the heart rate turn point. For these thresholds cardio-respiratory variables and percentages of maximum heart rate, heart rate reserve, maximum oxygen uptake and oxygen uptake reserve, and maximum power output were compared between groups. Additionally, the degree and direction of the deflection of the heart rate to performance curve (kHR) were compared between groups. Individuals with T1D had similar heart rate at LTP1 (mean difference) -11, [(95% confidence interval) -27 to 4 b.min-1], at VT1 (-12, -8 to 33 b.min-1) and at LTP2 (-7, -13 to 26 b.min-1), at VT2 (-7, -13 to 28 b.min-1), and at the heart rate turn point (-5, -14 to 24 b.min-1) (p = 0.22). Heart rate expressed as percentage of maximum heart rate at LTP1, VT1, LTP2, VT2 and the heart rate turn point as well as expressed as percentages of heart rate reserve at LTP2, VT2 and the heart rate turn point was lower in individuals with T1D (p < 0.05). kHR was lower in T1D compared to CON individuals (0.11 ± 0.25 vs. 0.51 ± 0.32, p = 0.02). Our findings demonstrate that there are clear differences in the heart rate response during CPX testing in individuals with T1D compared to CON individuals. We suggest using submaximal markers to prescribe exercise intensity in people with T1D, as the heart rate at thresholds is influenced by kHR. Clinical Trial Identifier: NCT02075567 (https://clinicaltrials.gov/ct2/show/NCT02075567).

SUBMITTER: Moser O

PROVIDER: S-EPMC6176070 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Different Heart Rate Patterns During Cardio-Pulmonary Exercise (CPX) Testing in Individuals With Type 1 Diabetes.

Moser Othmar O Tschakert Gerhard G Mueller Alexander A Groeschl Werner W Eckstein Max L ML Koehler Gerd G Bracken Richard M RM Pieber Thomas R TR Hofmann Peter P

Frontiers in endocrinology 20181002

To investigate the heart rate during cardio-pulmonary exercise (CPX) testing in individuals with type 1 diabetes (T1D) compared to healthy (CON) individuals. Fourteen people (seven individuals with T1D and seven CON individuals) performed a CPX test until volitional exhaustion to determine the first and second lactate turn points (LTP1 and LTP2), ventilatory thresholds (VT1 and VT2), and the heart rate turn point. For these thresholds cardio-respirator ...[more]

PMID: 30333794

Similar Datasets

Project description:BACKGROUND:Single measurements of left ventricular filling pressure at rest lack sensitivity for identifying heart failure with preserved ejection fraction (HFpEF) in patients with dyspnea on exertion. We hypothesized that exercise hemodynamic measurements (ie, changes in pulmonary capillary wedge pressure [PCWP] indexed to cardiac output [CO]) may more sensitively differentiate HFpEF and non-HFpEF disease states, reflect aerobic capacity, and forecast heart failure outcomes in individuals with normal PCWP at rest. METHODS AND RESULTS:We studied 175 patients referred for cardiopulmonary exercise testing with hemodynamic monitoring: controls (n=33), HFpEF with resting PCWP?15 mm Hg (n=32), and patients with dyspnea on exertion with normal resting PCWP and left ventricular ejection fraction (DOE-nlrW; n=110). Across 1835 paired PCWP-CO measurements throughout exercise, we used regression techniques to define normative bounds of "PCWP/CO slope" in controls and tested the association of PCWP/CO slope with exercise capacity and composite cardiac outcomes (defined as cardiac death, incident resting PCWP elevation, or heart failure hospitalization) in the DOE-nlrW group. Relative to controls (PCWP/CO slope, 1.2±0.4 mm Hg/L/min), patients with HFpEF had a PCWP/CO slope of 3.4±1.9 mm Hg/L/min. We used a threshold (2 SD above the mean in controls) of 2 mm Hg/L/min to define abnormal. PCWP/CO slope >2 in DOE-nlrW patients was common (n=45/110) and was associated with reduced peak Vo2 (P<0.001) and adverse cardiac outcomes after adjustment for age, sex, and body mass index (hazard ratio, 3.47; P=0.03) at a median 5.3-year follow-up. CONCLUSIONS:Elevated PCWP/CO slope during exercise (>2 mm Hg/L/min) is common in DOE-nlrW and predicts exercise capacity and heart failure outcomes. These findings suggest that current definitions of HFpEF based on single measures during rest are insufficient and that assessment of exercise PCWP/CO slope may refine early HFpEF diagnosis.

Project description:Functional assessments of cardiovascular fitness (CVF) are needed to establish animal models of dysfunction, test the effects of novel therapeutics, and establish the cardio-metabolic phenotype of mice. In humans, the graded maximal exercise test (GXT) is a standardized diagnostic for assessing CVF and mortality risk. These tests, which consist of concurrent staged increases in running speed and inclination, provide diagnostic cardio-metabolic parameters, such as, VO2max, anaerobic threshold, and metabolic crossover. Unlike the human-GXT, published mouse treadmill tests have set, not staged, increases in inclination as speed progress until exhaustion (PXT). Additionally, they often lack multiple cardio-metabolic parameters. Here, we developed a mouse-GXT with the intent of improving mouse-exercise testing sensitivity and developing translatable parameters to assess CVF in healthy and dysfunctional mice. The mouse-GXT, like the human-GXT, incorporated staged increases in inclination, speed, and intensity; and, was designed by considering imitations of the PXT and differences between human and mouse physiology. The mouse-GXT and PXTs were both tested in healthy mice (C57BL/6J, FVBN/J) to determine their ability to identify cardio-metabolic parameters (anaerobic threshold, VO2max, metabolic crossover) observed in human-GXTs. Next, theses assays were tested on established diet-induced (obese-C57BL/6J) and genetic (cardiac isoform Casq2-/-) models of cardiovascular dysfunction. Results showed that both tests reported VO2max and provided reproducible data about performance. Only the mouse-GXT reproducibly identified anaerobic threshold, metabolic crossover, and detected impaired CVF in dysfunctional models. Our findings demonstrated that the mouse-GXT is a sensitive, non-invasive, and cost-effective method for assessing CVF in mice. This new test can be used as a functional assessment to determine the cardio-metabolic phenotype of various animal models or the effects of novel therapeutics.

Project description:BackgroundThe use of wrist worn wearable fitness trackers has been growing rapidly over the last decade. The growing popularity can be partly attributed to the improvements in technology, making activity trackers more affordable, comfortable and convenient for use in different fitness and environmental applications. Fitness trackers typically monitor activity level, track steps, distance, heart rate (HR), sleep, peripheral capillary oxygen saturation and more, as the technology continuously is advancing. In terms of measuring HR, photoplethysmography (PPG) is a relatively new technology utilised in wearables. PPG estimates HR through an optical technique that monitors changes in blood volume beneath the skin. With these new products becoming available it is important that the validity of these devices be evaluated. Therefore, the aim of this study was to assess the validity of the Polar Vantage M (PVM) watch to measure HR compared to medical grade ECG on a healthy population during a range of treadmill exercise intensities.MethodsA total of 30 healthy participants (n = 17 males, n = 13 females) were recruited for this study. The validity of the PVM watch to measure HR was compared against the gold standard 5-lead ECG. The study was conducted on 2 separate testing days with 24-48 h between sessions. Participants completed the Bruce Treadmill Protocol, and HR was measured every 30 s. Validation of the PVM watch in comparison to the ECG was measured with an Intraclass Correlation Coefficient (ICC) and associated 95% confidence intervals (CI) and levels of agreement were identified with Bland-Altman plots with 90% limits of agreement. Linear regression analysis was performed to calculate the value of r 2 computing the variation of HR obtained by the PVM watch and ECG.ResultsIn total, 30 participants completed the protocol, with data from 28 participants utilised for statistical analysis (16 males, 14 females, 26.10 ± 3.39 years, height 52.36 m ± 7.40 cm, mass 73.59 ± 11.90 kg). A strong and significant correlation was found between the PVM watch and ECG, demonstrating good criterion validity (p < 0.05, r 2 = 0.87). Good validity was seen for day 1 and day 2 for stage 0 (ICC = 0.83; 95% CI [0.63-0.92], ICC = 0.74; 95% CI [0.37-0.88]), stage 1 (ICC = 0.78; 95% CI [0.52-0.90], ICC = 0.88; 95% CI [0.74-0.95]), and stage 2 (ICC = 0.88; 95% CI [0.73-0.94], ICC = 0.80; 95% CI [0.40-0.92]). Poor validity was demonstrated on day 1 and day 2 for stages 3-5 (ICC < 0.50).ConclusionThis study revealed that the PVM watch had a strong correlation with the ECG throughout the entire Bruce Protocol, however the level of agreement (LoA) becomes widely dispersed as exercise intensities increased. Due to the large LoA between the ECG and PVM watch, it is not advisable to use this device in clinical populations in which accurate HR measures are essential for patient safety; however, the watch maybe used in settings where less accurate HR is not critical to an individual's safety while exercising.

Dataset Information

Different Heart Rate Patterns During Cardio-Pulmonary Exercise (CPX) Testing in Individuals With Type 1 Diabetes.

Publications

Different Heart Rate Patterns During Cardio-Pulmonary Exercise (CPX) Testing in Individuals With Type 1 Diabetes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets